Mawer Investment Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$109M Buy
431,246
+121,366
+39% +$26.1M 0.74% 38
2026
Q1
$67.4M Buy
309,880
+48,482
+19% +$10.8M 0.44% 52
2025
Q4
$59.7M Buy
261,398
+10,550
+4% +$2.4M 0.33% 58
2025
Q3
$58.1M Buy
250,848
+6,854
+3% +$1.4M 0.3% 65
2025
Q2
$45.3M Sell
243,994
-14,740
-6% -$2.74M 0.23% 72
2025
Q1
$54.2M Sell
258,734
-3,416
-1% -$664K 0.26% 67
2024
Q4
$46.6M Sell
262,150
-13,186
-5% -$2.42M 0.21% 66
2024
Q3
$54.4M Sell
275,336
-14,746
-5% -$2.75M 0.25% 63
2024
Q2
$49.8M Sell
290,082
-3,683
-1% -$610K 0.24% 62
2024
Q1
$53.5M Sell
293,765
-3,462
-1% -$597K 0.25% 64
2023
Q4
$46.1M Buy
+297,227
New +$43.3M 0.24% 65

Other funds holding ABBV

Mawer Investment Management's ABBV Position: Q2 2026 in Review

Mawer Investment Management increased its AbbVie (ABBV) stake by 39% in Q2 2026, buying an estimated $26.1M and bringing the position to 431,246 shares worth $109M. The position accounts for 0.74% of the portfolio, ranked #38.

Mawer Investment Management first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Mawer Investment Management held 431,246 shares of AbbVie worth $109M as of Q2 2026.
  • Mawer Investment Management bought 121,366 AbbVie shares in Q2 2026, an estimated $26.1M.
  • AbbVie made up 0.74% of Mawer Investment Management's portfolio in Q2 2026, its #38 holding.
  • Mawer Investment Management first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
  • 4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Mawer Investment Management's 13F filing for Q2 2026, filed 7 Aug 2026.